Interventions for managing medication-related osteonecrosis of the jaw
Interventions for managing medication-related osteonecrosis of the jaw
Cochrane Review
17 SoF Entries
Summary of Findings
Key results and quality assessments using GRADE methodology
| Outcome | Effect | Participants | Studies | Certainty |
|---|---|---|---|---|
|
Xerostomia - Up to and including 6 months postRT
no treatment/placebo |
-0.35 | - | - | Not assessed |
|
Salivary flow rate (unstimulated) - Up to and including 3 months postRT
no treatment/placebo |
-0.06 | - | - | Not assessed |
|
Overall survival - Up to and including 6 months postRT
no treatment/placebo |
1.07 | - | - | Not assessed |
|
Quality of life - Up to and including 6 months postRT
no treatment/placebo |
0.2 | - | - | Not assessed |
|
sweating
no treatment/placebo |
2.98 | - | - | Not assessed |
|
adverse events, apart from for sweating
no treatment/placebo |
nan | - | - | Not assessed |
|
Xerostomia (0-4 scale - grade 2 or above) - 12 months postRT
no treatment/placebo |
0.7 | - | - | Not assessed |
|
Salivary flow rate (mg/5 min) (unstimulated) - 12 months postRT
no treatment/placebo |
0.32 | - | - | Not assessed |
|
Overall survival at 12 to 24 months postRT
no treatment/placebo |
1.18 | - | - | Not assessed |
|
Quality of life (Patient Benefit Questionnaire) - 12 months postRT
no treatment/placebo |
0.7 | - | - | Not assessed |
|
vomiting associated with amifostine (Adverse effects)
no treatment/placebo |
4.9 | - | - | Not assessed |
|
hypotension associated with amifostine(Adverse effects)
no treatment/placebo |
9.2 | - | - | Not assessed |
|
nausea associated with amifostine(Adverse effects)
no treatment/placebo |
2.6 | - | - | Not assessed |
|
allergic response associated with amifostine(Adverse effects)
no treatment/placebo |
7.51 | - | - | Not assessed |
|
Xerostomia (0-4 scale - grade 2 or above) - Up to and including 3 months postRT
placebo |
0.97 | - | - | Not assessed |
|
Overall survival at 42 to 72 months from baseline
placebo |
1.0 | - | - | Not assessed |
|
Adverse effects
placebo |
nan | - | - | Not assessed |
GRADE Certainty of Evidence:
High
Very confident in the effect estimate
Moderate
Moderately confident in the effect estimate
Low
Limited confidence in the effect estimate
Very Low
Very little confidence in the effect estimate
Review Information
| Review ID: | CD012744 |
| Outcomes: | 17 assessed |
Related Content
Evidence Quality Distribution:
Not assessed:
17